Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Alunacedase alfa (HrsACE2; GSK 2586881), a genetically modified human recombinant soluble angiotensin-converting enzyme-2 (hrsACE2), inhibits SARS-CoV-2 cell entry by competing with membrane-bound ACE2, offering potential in the research of SARS-CoV-2 [1] [2].
説明 | Alunacedase alfa (HrsACE2; GSK 2586881), a genetically modified human recombinant soluble angiotensin-converting enzyme-2 (hrsACE2), inhibits SARS-CoV-2 cell entry by competing with membrane-bound ACE2, offering potential in the research of SARS-CoV-2 [1] [2]. |
In vitro | Alunacedase alfa exhibits high-affinity binding to the SARS-CoV-2 spike glycoprotein, with an estimated affinity of roughly 1.2 nM [2]. |
別名 | HrsACE2, GSK 2586881 |
分子量 | N/A |
CAS No. | 2416824-55-8 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. 詳細
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Alunacedase alfa 2416824-55-8 Microbiology/Virology SARS-CoV HrsACE2 GSK 2586881 Inhibitor inhibitor inhibit